02:33 PM EDT, 07/11/2025 (MT Newswires) -- Novartis ( NVS ) has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in Delaware published Friday.

MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' ( NVS ) drug, according to a decision from US District Judge Richard Andrews.

The patent for the drug expires on November 8, 2026, the court document said.

Novartis ( NVS ) said it was "disappointed" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.

MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.

Novartis ( NVS ) shares were down 2% in recent trading.

Price: 121.29, Change: -2.44, Percent Change: -1.97